Compare BFRG & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFRG | ADIL |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6M | 10.2M |
| IPO Year | 2022 | 2017 |
| Metric | BFRG | ADIL |
|---|---|---|
| Price | $0.49 | $4.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | ★ 1.1M | 31.6K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.88 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $116,670.00 | N/A |
| Revenue This Year | $568.55 | N/A |
| Revenue Next Year | $573.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 79.49 | N/A |
| 52 Week Low | $0.43 | $0.13 |
| 52 Week High | $1.96 | $8.75 |
| Indicator | BFRG | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 62.80 |
| Support Level | $0.43 | $3.80 |
| Resistance Level | $0.69 | $6.26 |
| Average True Range (ATR) | 0.04 | 0.45 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 19.84 | 95.35 |
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. The Company is focused specifically on advance artificial intelligence and machine learning (AI/ML)- driven analysis of complex datasets in medicine and healthcare. The Company's objective is to use its AI/ML platform to provide a precision-medicine approach to drug-asset enablement through external partnerships and selective internal development.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.